# OnCo record nct07246863 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07246863/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07246863", "NCT07246863" ;
  schema:name "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC"@en ;
  schema:alternateName "GDFATHER-NSCLC-02"@en ;
  schema:description "A phase 2 trial of Visugromab, Nivolumab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07246863/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07246863> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-10-07" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/visugromab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/catalym/> .